Skip to main content
SpringerLink
Log in

Angiotensin

  • Book
  • © 1974

Overview

Editors:
  1. Irvine H. Page

    1. The Cleveland Clinic Foundation, Cleveland, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. F. Merlin Bumpus

    1. Division of Research, The Cleveland Clinic Foundation, Cleveland, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 37)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (30 chapters)

  1. Front Matter

    Pages N1-XIX
    Download chapter PDF

  2. The Biological Production of Angiotensin

    • Leonard T. Skeggs, Frederic E. Dorer, Joseph R. Kahn, Kenneth E. Lentz, Melvin Levine
    Pages 1-16

  3. The Fate of Angiotensin I

    • J. R. Vane
    Pages 17-40

  4. Converting Enzyme in Vitro Measurement and Properties

    • Y. S. Bakhle
    Pages 41-80

  5. The Fate of Angiotensin II

    • J. W. Ryan
    Pages 81-110

  6. Catabolism of Angiotensin II

    • J. G. Ledingham, W. P. Leary
    Pages 111-125

  7. Structure-Activity Relationship in Angiotensin II Analogs

    • M. C. Khosla, R. R. Smeby, F. M. Bumpus
    Pages 126-161

  8. Antagonists of Angiotensin II

    • R. K. Tรผrker, I. H. Page, F. M. Bumpus
    Pages 162-169

  9. Tachyphylaxis to Angiotensin

    • John M. Stewart
    Pages 170-184

  10. Immunogenicity and Antigenicity of Angiotensin I and II

    • M. B. Vallotton
    Pages 185-200

  11. Measurement of Renin and of Angiotensin (Extraction and Bioassay)

    • R. Boucher, J. Genest
    Pages 201-210

  12. Angiotensin Immunoassay

    • G. W. Boyd, W. S. Peart
    Pages 211-226

  13. Bioassay of Angiotensin

    • Philip A. Khairallah, Robert R. Smeby
    Pages 227-239

  14. Plasma of Serum Vasopressor Peptides Other than Angiotensins

    • H. R. Croxatto
    Pages 240-263

  15. Primary Aldosteronism: Importance of the Level of Plasma Renin as an Adjunct in Diagnosis

    • J. W. Conn, E. L. Cohen
    Pages 264-283

  16. Secondary Hyperaldosteronism

    • E. G. Biglieri, J. R. Stockigt, M. Schambelan, R. D. Collins
    Pages 284-297

  17. Intermediary Metabolism of Aldosterone

    • J. C. Melby
    Pages 298-321

  18. The Renin-Angiotensin System in the Control of Aldosterone Secretion

    • James O. Davis
    Pages 322-336

  19. Aldosterone Regulation in Sodium Deficiency: Role of Ionic Factors and Angiotensin II

    • J. R. Blair-West, J. P. Coghlan, D. A. Denton, B. A. Scoggins
    Pages 337-368

  20. Effects of Aldosterone on Blood Pressure, Water, and Electrolytes

    • F. Gross
    Pages 369-399
Back to top

Keywords

About this book

The history of arterial hypertension is both long and short; long, since BRIGHT (1827) first related hardness of the pulse to hardness of the kidneys and hyper. trophy of the heart; short in that modern research began in the late twenties. Most of what we know of these diseases has been discovered in the past fifty years. The modern story should have begun in 1897 when an extract of kidney was shown to be pressor. But little was done with knowledge until about 1929 when the relationship of this kidney extract called "renin" to hypertension was posยท tulated. The pressor effects were, however, unlike most of those seen with subยท stances such as epinephrine or vasopressin. Plasma was required for action of renin and the active substance appeared to be protein. In 1939, it was shown that renin was not in itself a pressor substance but rather a proteolytic enzyme which produced a powerful pressor substance acting on a substrate synthesized by the liver. Later it was noted that the first definable step after the formation of this peptide was cleaving of the decapeptide which had little or no demonstrable activity, with loss of two amino acids to form the octapeptide called "angiotensin". Within a decade synthesis was achieved which made the substance available for worldยทwide study.

Editors and Affiliations

  • The Cleveland Clinic Foundation, Cleveland, USA

    Irvine H. Page

  • Division of Research, The Cleveland Clinic Foundation, Cleveland, USA

    F. Merlin Bumpus

Bibliographic Information

  • Book Title: Angiotensin

  • Editors: Irvine H. Page, F. Merlin Bumpus

  • Series Title: Handbook of Experimental Pharmacology

  • DOI: https://doi.org/10.1007/978-3-642-65600-2

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin ยท Heidelberg 1974

  • Softcover ISBN: 978-3-642-65602-6Published: 11 November 2011

  • eBook ISBN: 978-3-642-65600-2Published: 06 December 2012

  • Series ISSN: 0171-2004

  • Series E-ISSN: 1865-0325

  • Edition Number: 1

  • Number of Pages: XX, 594

  • Topics: Medicine/Public Health, general, Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation